Chemotherapy, as one of the main options for cancer treatment, has limited selectivity for cancer cells, a narrow therapeutic window, and potential high toxicity, which restricts its clinical application. Antibody-drug conjugates (ADCs), as emerging anticancer therapeutics, can deliver highly cytotoxic molecules directly to cancer cells to exert their lethal effects. ADCs are formed by the … Read more
From “Magic Bullets” to the Birth of ADC Drugs As early as 1913, Paul Ehrlich first proposed the concept of “magic bullets” and drug targeting. However, it wasn’t until the rapid development of antibody technology in the 1970s that the first antibody-drug conjugate (ADC) — Gemtuzumab ozogamicin (GO), targeting CD33, was approved by the FDA … Read more
▉ Introduction Antibody-drug conjugates (ADCs) are composed of monoclonal antibodies that specifically target antigens linked to small molecule cytotoxic drugs via linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor-targeting capability of antibody drugs. ADCs consist of three main components: the antibody responsible for selectively recognizing cancer cell surface antigens, … Read more
–01– Introduction Antibody-drug conjugates (ADC) are known as “magic bullets” that precisely target tumor cells through antibodies, delivering cytotoxic drugs while combining the precision of targeted therapy with the potent killing power of chemotherapy. Over the past decade, ADCs have gradually matured in the treatment of solid tumors and hematological malignancies, becoming a revolutionary field … Read more
Clinical Development of ADCs for Solid Tumors The currently approved ADCs for solid tumors are listed in the table below: ADCs Target Indications T-DM1 HER2 HER2-positive metastatic breast cancer SG (sacituzumab govitecan) Trop2 Triple-negative breast cancer (TNBC) Metastatic urothelial carcinoma (mUC) sacituzumab tirumotecan Trop2 TNBC, NSCLC Gastric cancer/gastroesophageal junction cancer, mUC enfortumab vedotin Nectin-4 Locally … Read more
At this year’s AACR annual meeting, there were hundreds of details related to ADC drugs. Leading ADC company Daiichi Sankyo announced the latest research progress of its HER3-targeted ADC product Patritumab deruxtecan (HER3-DXd); AstraZeneca also disclosed research updates on several drugs including AZD9592 (bispecific ADC) and AZD5335 (FRα ADC). Many Chinese pharmaceutical companies also showcased … Read more
Synergizing Catalysis with Post-catalysis Pseudo-Iron Release by Building Dynamic Catalytic Active Sites in Diatomic Nanozymes for Boosting Cancer TherapyJournal of the American Chemical Society ( IF 14.4 ) Pub Date : 2025-04-25DOI: 10.1021/jacs.5c03804Diatomic nanozymes have significant potential in tumor therapy, but their therapeutic efficacy is often limited by their low catalytic activity. Here, we propose … Read more
01 DAC‘s Emergence and Advantages Cancer therapeutics need to balance efficacy and safety, even targeted chemotherapy does not always only kill abnormal cancer cells, and non-specific toxicity can lead to a low therapeutic index and side effects. The technology of Proteolysis-targeting chimeras (PROTACs), which achieve therapeutic effects by promoting the degradation of target proteins, is … Read more
After 2019, ADC drugs have been approved for marketing one after another, and the approval of Aidiqi in 2021 marked a milestone in the development of domestic ADC innovative drugs. The broad therapeutic prospects and huge market size have stimulated many pharmaceutical companies to ignite their enthusiasm for ADC drug research and development, leading the … Read more
Introduction Antibodies are one of the key components of ADC drugs, serving as precise guiding components with the functions of targeting and toxin delivery. They can specifically recognize the target antigens on the surface of tumor cells, delivering toxins to the tumor cells and mediating the localization and endocytosis of ADCs in tumor cells[1]. After … Read more